Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition.

ABSTRACT:

Objectives

The aim was to investigate whether switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/F/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) may improve neuropsychiatric symptoms and neurocognition.

Design

Pilot, single-arm, prospective study of persons with HIV (PWH) on the efficacy and safety of switching from EFV/F/TDF to BIC/F/TAF.

Methods

Participants underwent neuropsychological assessment (NPA) at switch (T0) and after 48 weeks (T1). NPA was carried out through a standardized battery of 12 tests. Neurocognitive impairment (NCI) was defined by a score of at least 1 standard deviation (SD) below the normal mean on at least two tests or ≥2 SD below on one test. Individual z scores were determined, NPZ-12 was calcula

SUBMITTER: Vergori A 

PROVIDER: S-EPMC11784908 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature